Halozyme Therapeutics, Inc. share price logo

Halozyme Therapeutics, Inc. Share Price

NASDAQ: HALO

Mid Cap

$76.33

-0.57

(-0.74%)

as on

Halozyme Therapeutics, Inc. Stock Performance

as on September 16, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $75.25
    $77.06
    downward going graph

    1.41%

    Downside

    0.96%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $42.01
    $77.6
    downward going graph

    44.96%

    Downside

    1.66%

    Upside

    downward going graph

Halozyme Therapeutics, Inc. share price movements today

Previous Close
$76.90
Open
$77.06
Volume
772.2K
Day's Low - High
$75.25 - $77.06
52 Week Low - High
$42.01 - $77.6

Halozyme Therapeutics, Inc. Historical Returns

1 Month Return
+ 14.32 %
3 Month Return
+ 42.46 %
1 Year Return
+ 23.43 %
3 Year Return
+ 81.67 %
5 Year Return
+ 179.33 %

Halozyme Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Halozyme Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$9.0B

EPS (TTM)

6.0528

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.85%

PE Ratio (TTM)

17.6

Industry PE ratio

10.127857142857144

P/B Ratio

17.5973

PEG Ratio

-2.5

EBITDA

758.6M

Revenue (TTM)

1.2B

Profit Margin

47.28%

Return On Equity TTM

179.14%

Halozyme Therapeutics, Inc. Stock Valuation

Track how Halozyme Therapeutics, Inc. P/E has moved over time to understand its valuation trends.

Halozyme Therapeutics, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (10.98x)

June 30, 2025

Industry (10.13x)

September 15, 2025

Today (17.60x)

September 15, 2025

Highest (174.04x)

September 30, 2020

LowHigh

Today’s Price to Earnings Ratio: 17.60x

Halozyme Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Halozyme Therapeutics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$9.0B179.33%17.647.28%
BUY$61.1B256.98%-505.15-12.96%
NA$38.7BNANA-3.89%
BUY$101.1B47.85%28.0731.86%
BUY$59.4B-3.43%14.1131.37%

Stock Returns calculator for Halozyme Therapeutics, Inc. Stock including INR - Dollar returns

The Halozyme Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Halozyme Therapeutics, Inc. investment value today

Current value as on today

₹1,27,505

Returns

₹27,505

(+27.51%)

Returns from Halozyme Therapeutics, Inc. Stock

₹22,520 (+22.52%)

Dollar Returns*

₹4,985 (+4.99%)

Analyst Recommendation on Halozyme Therapeutics, Inc. Stock

Based on 17 analysts

BUY

82.35%

Buy

17.65%

Hold

0.00%

Sell

Based on 17 analysts, 82.35% of analysts recommend a 'BUY' rating for Halozyme Therapeutics, Inc.. Average target price of $70.56

Halozyme Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Halozyme Therapeutics, Inc..

What analysts predicted

-8.18%DOWNSIDE

Target Price

$70.56

Current Price

$76.33

Analyzed by

17 Analysts

Target

$70.56

Halozyme Therapeutics, Inc. target price $70.56, a slight downside of -8.18% compared to current price of $76.33. According to 17 analysts rating.

Halozyme Therapeutics, Inc. Stock's Interest Amongst Investors

Search interest for Halozyme Therapeutics, Inc. Stock has increased by 90% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:90% versus previous 30 day period

Halozyme Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
162
221
216
230
195
231
290
298
264
325
Gross Profit
126
170
161
177
149
173
240
255
216
279
Operating Income
53
94
88
101
95
117
163
175
141
202
EBITDA
77
118
129
127
115
137
190
203
168
229
Interest Expense
4
4
4
5
4
4
4
4
4
4
Depreciation
17
20
20
20
20
20
20
20
20
20
Income Before Tax
52
93
101
101
96
117
165
178
143
204
Income Tax Expense
12
18
19
15
19
24
28
41
25
39
Net Income
39
74
81
85
76
93
137
137
118
165
Net Profit Margin
24.43%
33.82%
37.88%
37.12%
39.22%
40.30%
47.23%
45.98%
44.59%
50.71%

Halozyme Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
135
146
316
151
195
267
443
660
829
1,015
Gross Profit
105
113
285
141
150
224
361
520
636
855
Operating Income
-27
-83
81
-69
-67
144
275
267
337
551
EBITDA
-25
-80
83
-66
-63
147
278
315
451
656
Interest Expense
5
19
21
18
11
20
7
16
18
18
Depreciation
-
-
2
2
4
3
2
49
84
81
Income Before Tax
-32
-101
61
-79
-72
129
248
248
348
557
Income Tax Expense
3
1
-1
0
0
0
-154
46
66
113
Net Income
-32
-103
62
-80
-72
129
402
202
281
444
Net Profit Margin
-23.86%
-70.23%
19.89%
-52.90%
-36.86%
48.24%
90.84%
30.62%
33.96%
43.74%

Halozyme Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
74
81
85
76
93
137
137
118
165
Operating Cash Flow
66
132
102
129
55
115
178
154
99
Investing Cash Flow
54
-83
-8
-82
-42
-167
29
-90
84
Financing Cash Flow
2
4
-249
0
9
18
-246
-3
-298
Change in Cash
124
53
-155
46
23
-33
-38
60
-114

Halozyme Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-103
62
-80
-72
129
402
202
281
444
Operating Cash Flow
-50
134
-49
-85
55
299
240
388
479
Investing Cash Flow
-76
-163
2
-5
78
-406
-487
-96
-262
Financing Cash Flow
150
131
-63
153
-106
77
362
-407
-218
Change in Cash
23
101
-110
62
27
-28
115
-116
-2

Global Institutional Holdings in Halozyme Therapeutics, Inc.

Funds
Holdings
BlackRock Inc
14.61%
Vanguard Group Inc
10.97%
State Street Corp
5.17%
Amvescap Plc.
3.33%
Snyder Capital Management LP
3.14%

Insights on Halozyme Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, HALO stock has moved up by 13.5%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 118.09M → 165.16M (in $), with an average increase of 28.5% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 264.86M → 325.71M (in $), with an average increase of 18.7% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 34.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 70.6% return, outperforming this stock by 49.3%

About Halozyme Therapeutics, Inc.

we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
OrganisationHalozyme Therapeutics, Inc.
Headquarters12390 El Camino Real, San Diego, CA, United States, 92130
IndustryHealth Technology
CEODr. Helen I. Torley M.B. Ch. B., M.R.C.P.
E-voting on sharesClick here to vote

Key Management of Halozyme Therapeutics, Inc.

Name

Title

Mr. Mark Snyder Esq.

Senior VP, General Counsel, Chief Compliance Officer & nd Secretary

Ms. Cortney Caudill M.B.A.

Chief Operations Officer

Ms. Tram Bui

Head of Investor Relations & Corporate Communications

Ms. Amy Marinne Fox

Chief Human Resources Officer

Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.

President, CEO & Director

Ms. Nicole LaBrosse CPA

Senior VP & CFO

Mr. Paul Spence

Chief Commercial Officer

Dr. Christopher Wahl M.B.A., M.D.

Chief Business Officer

Dr. Charles P. Theuer M.D., Ph.D.

Chief Medical Officer

FAQs

What is Halozyme Therapeutics, Inc. share price today?

Halozyme Therapeutics, Inc. share price today is $76.33 as on at the close of the market. Halozyme Therapeutics, Inc. share today touched a day high of $77.06 and a low of $75.25.

What is the 52 week high and 52 week low for Halozyme Therapeutics, Inc. share?

Halozyme Therapeutics, Inc. share touched a 52 week high of $77.6 on and a 52 week low of $42.01 on . Halozyme Therapeutics, Inc. stock price today i.e. is closed at $76.33,which is 1.63% down from its 52 week high and 81.69% up from its 52 week low.

What is Halozyme Therapeutics, Inc.'s market capitalisation today?

Halozyme Therapeutics, Inc. market capitalisation is $0.01T as on .

How to invest in Halozyme Therapeutics, Inc. Stock (HALO) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Halozyme Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Halozyme Therapeutics, Inc. Shares that will get you 0.0197 shares as per Halozyme Therapeutics, Inc. share price of $76.33 per share as on September 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy Halozyme Therapeutics, Inc. Stock (HALO) from India?

Indian investors can start investing in Halozyme Therapeutics, Inc. (HALO) shares with as little as ₹88.141 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Halozyme Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Halozyme Therapeutics, Inc. share’s latest price of $76.33 as on September 16, 2025 at 1:29 am IST, you will get 0.1310 shares of Halozyme Therapeutics, Inc.. Learn more about fractional shares .

What are the returns that Halozyme Therapeutics, Inc. has given to Indian investors in the last 5 years?

Halozyme Therapeutics, Inc. stock has given 179.33% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?